Frailty Syndrome
1
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Martin PharmaceuticalsNY - New York
1 programPhysical Performance Assessment in Kidney Transplant EvaluationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Meridigen BiotechUMC119-06-05
Martin PharmaceuticalsPhysical Performance Assessment in Kidney Transplant Evaluation
Human BioSciencesLess-volume
Clinical Trials (3)
Total enrollment: 101 patients across 3 trials
Mesenchymal Stem Cells for The Treatment of Frailty Syndrome
Start: Sep 2021Est. completion: Jul 20256 patients
Phase 1Unknown
Physical Performance Assessment in Kidney Transplant Evaluation
Start: Oct 2025Est. completion: Oct 202850 patients
N/ARecruiting
TrackFrailty Project
Start: Jun 2025Est. completion: Jul 202645 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 101 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.